Clarivate Q2 Revenue Misses Slightly, But EPS Beats; Guidance Reaffirmed
CLVT sits 39% above its 52-week low of $1.66.
Summary
Clarivate's Q2 revenue of $587.3M missed the $589.7M consensus by less than 1%, while adjusted EPS of $0.19 beat by a penny. The revenue decline was driven by divestitures and product group wind-downs, partially offset by 0.7% organic subscription growth. Adjusted EBITDA of $247.2M also missed estimates. Management reaffirmed full-year 2026 guidance, signaling confidence despite the top-line softness. This follows the July 6 announcement of the $600M Life Sciences & Healthcare divestiture, which is expected to reshape the business. The slight miss and reaffirmed outlook suggest the quarter was largely in line, but the ongoing transition away from transactional revenue bears watching.
At the time of this announcement, CLVT was trading at $2.31 on NYSE in the Technology sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $1.66 to $4.77. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.